首页> 外文期刊>Biochemical Pharmacology >Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels.
【24h】

Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels.

机译:茚地那韦通过增加激活的固醇调节元件结合蛋白的水平和降低胆固醇7α-羟化酶mRNA的水平来改变原代大鼠肝细胞中的固醇和脂肪酸稳态机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Human immunodeficiency virus protease inhibitors induce hyperlipidemia in many patients treated with these drugs. We examined the effects of indinavir on cholesterol and bile acid homeostatic mechanisms in a primary rat hepatocyte (PRH) culture model. In PRH, indinavir up-regulated (2.5-fold) 3-hydroxy-3-methylglutaryl-Coenzyme A reductase mRNA levels 24hr after drug addition. In these same experiments, cholesterol 7alpha-hydroxylase (CYP7A1) mRNA levels, the rate-limiting enzyme in bile acid biosynthesis, was decreased up to 10-fold. Fatty acid synthase mRNA levels were up-regulated more than 3-fold under these conditions. Indinavir did not alter CYP7A1 transcriptional activity, but decreased CYP7A1 mRNA half-life in PRH from 1.5hr to less than 0.5hr. Sterol regulatory element-binding protein-1 (SREBP-1) mature form was increased approximately 6-fold by this drug. Indinavir-induced mRNA changes and SREBP-1 mature protein levels were significantly abated by the addition of cholesterol, solubilized in beta-cyclodextrin, to culture medium. Indinavir markedly decreased endogenous cholesterol esterification and increased cholesterol in intracellular membranes in primary hepatocytes. Indinavir gavaged into intact mice also markedly increased SREBP-1 and SREBP-2 (mature forms) in hepatic nuclei. CYP7A1 mRNA was also decreased approximately 52% in indinavir-treated animals. We propose that indinavir disrupts cellular cholesterol homeostasis by increasing SREBP's and decreasing CYP7A1 mRNA.
机译:人类免疫缺陷病毒蛋白酶抑制剂在许多用这些药物治疗的患者中诱发高脂血症。我们检查了茚地那韦对原代大鼠肝细胞(PRH)培养模型中胆固醇和胆汁酸稳态机制的影响。在PRH中,茚地那韦在添加药物后24小时会上调(2.5倍)3-羟基-3-甲基戊二酰辅酶A还原酶mRNA的水平。在这些相同的实验中,胆汁酸生物合成中的限速酶胆固醇7α-羟化酶(CYP7A1)mRNA水平降低了10倍。在这些条件下,脂肪酸合酶mRNA水平上调了3倍以上。茚地那韦不改变CYP7A1的转录活性,但将PRH中CYP7A1 mRNA的半衰期从1.5小时降低至小于0.5小时。该药物使甾醇调节元件结合蛋白1(SREBP-1)的成熟形式增加了约6倍。通过将溶于β-环糊精的胆固醇添加到培养基中,可显着减轻茚地那韦诱导的mRNA变化和SREBP-1成熟蛋白水平。茚地那韦显着降低原发性肝细胞内源性胆固醇酯化作用,并增加胆固醇水平。进入完整小鼠的茚地那韦也显着增加了肝核中的SREBP-1和SREBP-2(成熟形式)。在用茚地那韦治疗的动物中,CYP7A1 mRNA也降低了约52%。我们建议茚地那韦通过增加SREBP's和降低CYP7A1 mRNA来破坏细胞胆固醇稳态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号